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Leber	congenital	amaurosis	(LCA)	is	a	rare	degenerative	eye	disease,	linked	to	mutations	in	at	least	14	genes.	
A	recent	gene	therapy	trial	in	patients	with	LCA2,	who	have	mutations	in	RPE65,	demonstrated	that	subretinal	
injection	of	an	adeno-associated	virus	(AAV)	carrying	the	normal	cDNA	of	that	gene	(AAV2-hRPE65v2)	could	
markedly	improve	vision.	However,	it	remains	unclear	how	the	visual	cortex	responds	to	recovery	of	retinal	
function	after	prolonged	sensory	deprivation.	Here,	3	of	the	gene	therapy	trial	subjects,	treated	at	ages	8,	9,	
and	35	years,	underwent	functional	MRI	within	2	years	of	unilateral	injection	of	AAV2-hRPE65v2.	All	subjects	
showed	increased	cortical	activation	in	response	to	high-	and	medium-contrast	stimuli	after	exposure	to	the	
treated	compared	with	the	untreated	eye.	Furthermore,	we	observed	a	correlation	between	the	visual	field	
maps	and	the	distribution	of	cortical	activations	for	the	treated	eyes.	These	data	suggest	that	despite	severe	
and	long-term	visual	impairment,	treated	LCA2	patients	have	intact	and	responsive	visual	pathways.	In	addi-
tion,	these	data	suggest	that	gene	therapy	resulted	in	not	only	sustained	and	improved	visual	ability,	but	also	
enhanced	contrast	sensitivity.
Introduction
Leber congenital amaurosis (LCA) is a rare eye disease, usually inher-
ited in an autosomal-recessive fashion. It is symptomatic at birth or 
within the first few months of life and affects around 1 in 81,000 
people (1). LCA has been associated with at least 14 different genes 
(2, 3). The gene encoding retinal pigment epithelium–specific pro-
tein 65 kDa (RPE65) is involved in one of the more common forms 
of LCA, the congenital blindness disorder LCA2 (4, 5). LCA2 patients 
are good candidates for gene transfer therapy, as the degeneration 
of retinal cells is delayed several years after initial symptoms. Stud-
ies in animal models of LCA2 (6–10) and, more recently, in humans 
(11–17) using adeno-associated virus–mediated (AAV-mediated) 
retinal gene delivery have demonstrated success in restoring retinal 
and visual function using one or more measures, including visual 
acuity (VA), visual fields (VFs), light sensitivity, pupillary light reflex, 
and/or mobility. Of all sensory systems, vision is processed by the 
largest brain area. Early onset of blindness can lead to structural and 
functional brain changes. It is not presently known whether severe 
impairment of the visual pathway caused by LCA2 would limit the 
responsiveness of neurons in the visual cortex. This question has been 
partially answered in a functional brain study performed in an ani-
mal model of LCA2 (18). Aguirre et al. reported cortical responses in 
5 RPE65 mutant dogs after bilateral treatment, 3 untreated affected 
dogs, and 2 normal dogs (18). All animals underwent functional 
MRI (fMRI) with checkerboard pattern stimuli presented bilater-
ally under intense, bright light (2.8 log cd∙m–2). fMRI results from 
this study showed dramatic visual cortical response for the treated 
as compared to untreated dogs. Aguirre and colleagues only looked 
at bright light responses and also grouped the results from dogs/eyes 
of different ages and with different sites of injection, so that details 
of the retinotopic projections could not be appreciated (18). Aguirre 
and colleagues also performed fMRI on untreated human LCA2 sub-
jects using stimuli of uniform light intensity varying from low to very 
high brightness. fMRI results showed that untreated LCA2 human 
subjects show cortical responses after illumination with extremely 
bright light and high contrast stimuli while no cortical response 
was observed with dim light (18). While other studies have looked at 
brain changes in blind-at-birth individuals or those with blindness 
acquired after early childhood (19, 20), there is limited information 
about brain function in human subjects following recovery of retinal 
function after a long period of visual deprivation.
The present study was carried out in human LCA2 patients to 
investigate how the cortex responds to the recovery of function after 
gene therapy in specific areas of the retina after prolonged visual 
deprivation. In contrast to the study by Aguirre et al. (18), the current 
study used only dim light stimuli, since it is known that young LCA2 
patients are able to see and function (albeit poorly) when their envi-
ronment is flooded with light (21–23). Also, to account for variability 
in the disease stage among study participants and to correlate fMRI 
results with each subject’s behavioral measures, functional analyses 
were carried out separately for each individual patient. LCA2 sub-
jects were injected unilaterally in their worst-seeing eye — so labeled 
based on both qualitative and quantitative tests as well as self reports. 
However, the differences in function between the eyes, based on VA, 
VF, light sensitivity, and imaging studies, was minimal (16, 17). The 
untreated eye served as an internal control for each subject. As an 
additional control, we performed fMRI on a normally sighted indi-
vidual, age and sex matched to 2 of the 3 LCA2 participants.
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Results
Clinical visual function measures
Each subject underwent comprehensive baseline and serial postinjec-
tion retinal/visual function testing (16, 17) at prescribed time points 
(baseline; days 1–3, 14, 30, 60, 90, 180, and 270; and through day 
365 for subject CH13, year 1.5 for CH09, and year 2 for CH08) after 
their assent/consent to enroll in the gene transfer study (16), prior 
to enrollment in the fMRI study. Each subject demonstrated both 
subjective and objective improvement in multiple parameters after 
administration of AAV2-hRPE65v2, including expansion of the VFs 
(Figures 1, 2, and 3). Improvements at day 365 (subjects CH09 and 
CH08) and day 180 (subject CH13) after injection have been previ-
ously described (16). The findings for the subjects at the time of fMRI 
(compared with baseline measurements) are summarized below.
Full-field sensitivity threshold testing. All subjects showed significant 
improvements in full-field sensitivity threshold testing in the 
injected eye only (16). There were greater than 10-dB differences in 
light sensitivity of the injected versus uninjected eyes at all postin-
jection time points.
Pupillometry light reflex. All subjects showed significantly improved 
amplitudes and velocities of constriction after illumination of the 
injected eye only (16). Each individual subject showed a greater 
than 10-fold decrease in the light intensity threshold required to 
generate a pupillary light reflex in their injected eye.
Ocular motility/position. There was a slight decrease in the velocity 
of nystagmus (but no change in amplitude) in CH08’s eyes at the 
1.5-year time point compared with baseline. The other 2 subjects 
did not have significant nystagmus at either baseline or the time 
of fMRI. In addition, both before and after injection, the following 
Figure 1
Results for subject CH09. (A) fMRI results 
for high-contrast stimulus presented to the 
treated left eye showed significant (fdr < 5%, 
corrected P < 0.005, cca ≥ 100 mm2) bilat-
eral activations extending from medial to lat-
eral aspects of the occipital poles. All fMRI 
results show left and right inflated (medial 
view) and flatmap cortical representations. 
(C) Medium-contrast stimulus presented 
to the left eye also showed significant 
(fdr < 5%, corrected P < 0.002, cca ≥ 20 
mm2) bilateral activations. Activations for 
high- and medium-contrast stimuli were pri-
marily distributed to the upper bank of the 
CF. (B) The high-contrast stimulus presented 
to the untreated right eye showed patches of 
activation outside the primary visual cortex 
at a lower (uncorrected) statistical threshold 
and a smaller extent threshold. (D) No acti-
vation, even at an uncorrected relaxed sta-
tistical threshold, was detected for the right 
eye presented with the medium-contrast 
stimulus. (E and F) Measured VFs at base-
line (before surgery) and at follow-up. (G) 
The predicted VF area in E was based on 
the observed subretinal injection site at the 
time of treatment, indicated by white arrow-
heads within the composite retinal fundus 
image. CH09’s predicted VF was symmetric 
to the vertical meridian with a greater area 
below than above the horizontal meridian. 
Such VF distribution is predictive of cortical 
activation that is symmetrically distributed to 
both hemispheres, with a larger area of acti-
vation in the upper bank of the CF. CH09’s 
fMRI results partially correlated with both 
predicted and measured VFs.
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patient-specific observations were made about eye position: CH09, 
who is myopic and requires correction of 12.5 diopters, displayed 
a left eye exotropia when his glasses were removed; CH13 showed 
esotropia of his right eye; except for the nystagmus, there were no 
anomalies noted in CH08’s gaze.
Mobility testing. Mobility was assessed using navigation through 
a standardized obstacle course (15–17). CH09 and CH08 showed 
improved navigation through the course and were able to navigate 
the course in dim light (injected eye only) (16). No significant chang-
es were observed for CH13 compared to his baseline performance.
VA. There were no significant changes in VA in either eye in 
CH09 with VAs in both treated and untreated eyes of ~Log-
MAR 1.0 (20/200) at baseline and at year 1. There was a trend of 
improvement (albeit not statistically significant) in CH13’s VAs 
(both eyes), with injected eye at LogMAR ~1.9 (~20/1,589) at base-
line and LogMAR ~1.61 (~20/815) at year 1. There was a gradual 
decline over time in the VA of CH08’s treated eye (from LogMAR 
~1.31 to ~1.53 over 2 years).
Contrast sensitivity. There were no significant changes in contrast sen-
sitivity in any of the eyes/subjects, as assessed with the Pelli-Robson 
contrast sensitivity chart, prior to and after gene transfer (16, 17).
fMRI results
Each subject provided assent or consent to enroll in the fMRI study 
after subretinal injections had been administered. All fMRI analyses 
were performed using the general linear model (GLM) and the con-
trast of active blocks less the rest blocks as implemented in Brain-
VoyagerQX software (Methods and ref. 24). fMRI results showed 
substantial cortical activation in and around the visual cortex for 
LCA2 subjects after presentation of full-field contrast-reversing 
Figure 2
Results for subject CH08. (B) fMRI results 
showed significant (fdr < 5%, corrected 
P < 0.005, cca ≥ 100 mm2) bilateral acti-
vations in the primary visual cortex extend-
ing from medial to lateral and posterior to 
anterior aspects of the occipital cortex 
after presentation of high-contrast stimuli 
to the treated right eye. (A) In contrast, the 
untreated left eye was nearly unresponsive 
to the high-contrast stimuli, with activation 
detectable only at a less stringent statistical 
threshold and much lower extent threshold 
(uncorrected P < 0.005, cca ≥ 50mm2). (D) 
Activation for medium-contrast stimuli pre-
sented to the treated eye was also bilat-
eral, but with slightly more activation in 
the right hemisphere (fdr < 5%, corrected 
P < 0.004, cca ≥ 50 mm2). (C) No cortical 
activation was observed with the untreated 
eye exposed to the medium-contrast stimuli. 
(E and F) Measured VFs at baseline (before 
surgery) and at follow-up. (G) The predicted 
VF area in E was based on the observed 
subretinal injection site at the time of treat-
ment, indicated by white arrowheads within 
the composite retinal fundus image (taken 
just prior to surgery). Based on the injection 
site located superior to the macula, the por-
tion of the VF predicted to improve was the 
central inferior field. Such a VF is predictive 
of activation distributed bilaterally with the 
activation primarily located in the superior 
portion of the CF. CH08’s fMRI results were 
equally distributed about the CF and cor-
related more with his measured VFs. How-
ever, as suggested by the predicted and 
measured VFs, activation was distributed 
roughly equally to both hemispheres.
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(8 Hz) checkerboard stimuli at high and medium contrasts to their 
treated eye. None of the patients showed any cortical activation 
for the low-contrast stimuli with their treated or untreated eye. 
Presentation of the same stimuli to the untreated eye of all LCA2 
subjects did not result in significant cortical activations for the 
high- or medium-contrast stimuli.
CH09 showed highly significant (false discovery rate [fdr] < 5%, 
corrected P < 0.005, continuous connected area [cca] ≥ 100 mm2), 
bilateral activation in response to the high-contrast stimulus for 
his left eye at 580 days after injection (Figure 1A). A major portion 
of the activation occurred in the upper bank of the calcarine fissure 
(CF) in both the right and left hemispheres. The medium-contrast 
stimulus also induced significant bilateral activation (fdr < 5%, 
corrected P < 0.002, cca ≥ 20 mm2), primarily in the upper por-
tion of the CF (Figure 1C). As shown in Figure 1A, the main body 
of visual activation occurred in the lateral cortex. Although bilat-
eral, there was a slightly greater amount of activation in the left 
hemisphere extending to the parietal, temporal, and ventral occipi-
tal areas. CH09 did not present with activation in the occipital 
pole, corresponding to a lack of foveal activation (Figure 1A). The 
subject’s fMRI results for the untreated right eye with high-con-
trast stimulus showed patches of activation outside the primary 
visual cortex, at a much less stringent statistical threshold that was 
not corrected for multiple comparisons (uncorrected P < 0.002, 
cca ≥ 20 mm2; Figure 1B). No cortical activation was observed 
for the untreated eye in response to the medium-contrast stimu-
lus, even at an uncorrected and very relaxed statistical threshold 
(uncorrected P < 0.01; cca ≥ 20 mm2).
After gene therapy, the VF of CH09 (Figure 1, E and F) was consider-
ably extended compared with that before surgery. The predicted VF, 
Figure 3
Results for subject CH13. (B) fMRI results 
1 year after gene transfer for the treated 
right eye presented with the high-contrast 
stimuli showed significant (fdr < 5%, cor-
rected P < 0.003, cca ≥ 100 mm2) unilat-
eral cortical activation, primarily confined 
to the left lateral occipital lobe. (A) No 
activation was observed after exposure of 
the untreated left eye to the high-contrast 
stimuli. No activation was observed after 
medium-contrast stimulus was presented 
to the treated (D) or untreated (C) eye. (E 
and F) Measured and predicted VFs. The 
predicted VF for the treated eye showed a 
lateralized predicted VF in the lower right 
quadrant. This predicted VF was mostly 
confined to the right of the vertical meridian 
and located primarily below the horizontal 
meridian. Such distribution predicts cortical 
activation in the left upper area of the cor-
tex, with no activation in the contralateral 
hemisphere. The island of activation for the 
treated eye occurred in the predicted hemi-
sphere (see B), although it was located far 
lateral to primary visual cortex. (G) These 
results are consistent with the location of 
CH13’s subretinal injection. Composite of 
retinal fundus images demonstrating pig-
mentary deposits, vascular attenuation, 
and “window defects” caused by degener-
ation particularly in the central macula. As 
a result, CH13 had a subretinal injection 
located more peripheral (predominantly 
superotemporal to the macula).
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based on the observed subretinal injection site at the time of treat-
ment (Figure 1G), was symmetric to the vertical meridian, but covered 
a greater area below than above the horizontal meridian (Figure 1E).
CH08 showed highly significant bilateral activation to the high-
contrast stimulus (fdr < 5%, corrected P < 0.005, cca ≥ 100 mm2) for 
his right eye (728 days after injection; Figure 2B). Visual activation 
extended from the posterior to the anterior aspects of occipital cor-
tex on the medial, lateral, and ventral surfaces of the visual cortex. 
The medium-contrast stimulus for the treated eye of CH08 also 
evoked significant activation (fdr < 5%, corrected P < 0.004, cca ≥ 50 
mm2), which was bilateral, with slightly more activation in the right 
hemisphere (Figure 2D). The pattern of activation included a larger 
portion of activation in the superior bank of the CF. In contrast, the 
subject’s untreated left eye was nearly unresponsive to the high-con-
trast stimulus, with activation detectable only at a much less strin-
gent statistical threshold and much lower extent threshold (uncor-
rected P < 0.005, cca ≥ 50 mm2; Figure 2A). No cortical activation was 
observed for the untreated eye in response to the medium-contrast 
stimulus (Figure 2C), even at a very relaxed statistical threshold.
CH08’s VF maps (Figure 2, E and F) showed considerable 
improvement after injection compared with baseline. Based on the 
area of subretinal injection, which was localized to the superior 
macula (Figure 2G), the portion of the VF predicted to improve 
was the central inferior field (Figure 2E). In contrast to the sub-
ject’s treated eye, the follow-up VF of the untreated eye was smaller 
than that at baseline (Figure 2F).
CH13’s fMRI results for the high-contrast stimulus showed sig-
nificant (fdr < 5%, corrected P < 0.003, cca ≥ 100 mm2) cortical 
activation in the left lateral and ventral occipital lobe (370 days 
after injection; Figure 3B). The clusters of activation for CH13 
were primarily anterior in location, with almost no activation in 
the posterior aspects of the occipital cortex. The subject did not 
demonstrate any activation for the medium-contrast stimulus 
presented to the treated right eye (Figure 2D). In contrast to his 
treated eye, there was no cortical activation, even at an uncorrected 
and very relaxed statistical threshold, for the untreated left eye for 
either high- or medium-contrast stimulus (uncorrected P < 0.01; 
cca ≥ 50 mm2; Figure 3, A and C).
Comparison of pre- and postinjection VFs in CH13 showed pro-
gressive VF loss in the untreated eye (Figure 3E). The VF in the 
treated eye expanded considerably after subretinal injection (Fig-
ure 3F). Because of the advanced disease in CH13, AAV2-hRPE65v2 
was delivered supratemporally to the macula of his right eye, an 
area with better retinal quality (Figure 3G). The VF predicted based 
on the injection site was localized to the right hemifield and was 
primarily inferior (Figure 3F).
We also performed vision tests for a 10-year-old normal control 
subject, NC01 (age and sex matched to LCA2 patients CH08 and 
CH09), which showed normal vision for both right and left eyes 
(Figure 4 and data not shown). The subject demonstrated sig-
nificant bilateral activation for the high-contrast stimulus for his 
right eye (fdr < 5%, corrected P < 0.003, cca ≥ 100 mm2; Figure 4A). 
NC01’s visual activation extended from the posterior to the ante-
rior aspects of the occipital cortex, primarily on the medial and 
partially on the lateral and ventral surfaces of the visual cortex. 
Activation was distributed symmetrically to the upper and lower 
banks of the CF in both right and left hemispheres. The medium-
contrast stimulus also induced significant bilateral activation 
(fdr < 5%, corrected P < 0.002, cca ≥ 200 mm2; Figure 4B). Similar to 
the high-contrast stimulus, fMRI activation for the medium-con-
trast stimulus was distributed from the posterior to the anterior 
aspects of the occipital cortex. Similar to the LCA2 participants, 
NC01 did not present with any activation in the occipital pole 
Figure 4
Results for control subject NC01. Because vision tests showed nor-
mal vision for both left and right eyes, results from the right eye only 
are shown. fMRI results showed significant (fdr < 5%, corrected 
P < 0.003, cca ≥ 100 mm2) bilateral activations in the primary visual 
cortex extending from posterior to anterior and medial to some lateral 
aspects of the occipital cortex after presentation of high-contrast (A) 
and medium-contrast (B) stimuli to his right eye. Medial cortex activa-
tion was distributed symmetrically to the upper and lower banks of 
the CF in both the right and left hemispheres. Similar to the LCA2 
participants, and as predicted based on the scotopic light stimulus 
and/or the size of squares used in the checkerboard stimuli, NC01 did 
not show any activation in the occipital pole, where foveal activation 
would otherwise be represented. (C) VF map, which shows symmetri-
cal distribution with respect to the horizontal meridian but covers a 
greater area to the right of the vertical meridian. Such VF is predictive 
of bilateral fMRI activations that are equally spread to the superior and 
inferior aspects of CF. In agreement with his VF, activation was dis-
tributed equally to superior and inferior aspects of CF for both hemi-
spheres. Also, as predicted by his VF, activations were bilateral with 
slightly more activation in the left lateral visual cortex.
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(foveal activation). NC01 presented with ventral and temporal acti-
vation for both high and medium contrasts, with a slightly greater 
distribution in the left hemisphere. The subject’s VF showed a 
symmetrical distribution with respect to the horizontal meridian 
covering a greater portion of the right VF (Figure 4C). Similar cor-
tical activation was observed in 2 additional normal-sighted con-
trols, not age and sex matched (data not shown).
Discussion
To our knowledge, it was not previously known whether severe 
impairment of the visual pathway caused by congenital or early-
onset inherited retinal degeneration limits the responsiveness of 
neurons in the visual cortex that normally process vision. Here 
we showed definitively, through a combination of psychophysical 
testing and fMRI measurements, that gene augmentation therapy 
in humans with LCA2 rendered the retina (and visual cortex) far 
more sensitive to dimmer light and lower-contrast stimuli.
The site of injection for each patient varied according to the pro-
gression of the disease and the area of the retina in which there 
was evidence of sufficient (albeit unhealthy) retinal cells (16, 17). 
Since results were analyzed individually for each eye/patient (and 
not grouped, as is done in most other studies), it was possible to 
correlate the retinal injection site with the area of cortical activa-
tion. The fMRI experiment used dim light stimuli that had been 
imperceptible by the subjects prior to intervention (and remained 
imperceptible to the untreated eye).
As predicted, based on the retinal function tests, cortical activa-
tion was generally observed in regions corresponding to the area of 
retina that had been exposed to AAV2-hRPE65v2 by injection and 
immediate postinjection positioning. For CH09, fMRI results from 
his treated eye showed bilateral activations for high- and medium-
contrast stimuli. Based on the retinal injection site in the superior 
macula, the subject had a predicted VF that was symmetrical with 
respect to the vertical meridian and covered a greater area below 
than above the horizontal meridian. Such VF distribution is predic-
tive of bilateral cortical activations with activations more distrib-
uted to the superior portion of the CF than the inferior portion for 
both hemispheres. CH09’s pattern of activations partially correlated 
with the predicted VF: activations were more distributed to the supe-
rior portion of the CF and were bilateral. However, interestingly, 
more activation was observed in the left hemisphere. Although the 
reason for this asymmetric distribution is not known, it may sug-
gest some level of brain plasticity, or it may be due to the degree of 
retinal cell degenerations distributed along his retina. For example, 
if retinal cells were more viable and healthier in the temporal as 
opposed to nasal retina, it would produce greater ipsilateral cortical 
activation as opposed to contralateral activation.
CH08 presented with highly significant bilateral activations for 
the high- and medium-contrast stimuli presented to his treated 
eye. Compared with that of CH09, CH08’s activation was symmet-
rically distributed and more significant. Observed differences in 
activation between CH08 and CH09 may be attributed to the fact 
that CH08 had a thicker retina, identified at the time of surgery, or 
may be due to longer recovery after treatment for CH08 (2 years) 
compared with CH09 (1.5 years). Like CH09, CH08’s injection was 
delivered centrally (superior macula), and the VF predicted by the 
injection site extended inferiorly to the horizontal meridian and 
stretched to the lower-right quadrant. As suggested by the pre-
dicted field, CH08 presented with bilateral activation; however, 
the distribution of the visual activation correlated even better 
with the measured Goldmann VF, with activation extended from 
the posterior to the anterior visual cortex and distributed equally 
superior and inferior to the CF for both hemispheres, with slightly 
more activation in the left hemisphere.
Given the lack of viable cells in the macula of subject CH13 (Fig-
ure 3G), the patient had a subretinal injection located more periph-
eral than those in CH09 and CH08. For CH13, cortical activation 
was confined to the left hemisphere, corresponding to projections 
from the nasal retina in the treated eye. However, although activa-
tion was located only in the left occipital cortex, it was more lateral 
and basal than expected. This may represent activation of associa-
tion cortex processing inputs to primary visual cortex that were 
below the level of detection, or increased attention to the button 
press during the task (25, 26). Alternatively, it could indicate plastic-
ity of cortical neuronal connectivity due to the disease/treatment. 
In any case, the results from this subject with severe retinal/macular 
degenerative changes provide hope for gene therapy–mediated res-
toration of at least some visual function (i.e., VFs, light sensitivity) 
in other patients with end-stage LCA or retinitis pigmentosa.
Preservation of expected retinotopy has been identified in another 
patient who had partial vision restored in adulthood after having 
been blinded in early childhood (19, 20). Functional reorganiza-
Figure 5
fMRI stimuli and design. (A) Checkerboard stimuli with a constant light intensity of 5 lux, at 3 levels of contrast (high, 100%; medium, 34%; low, 
10%), were presented in a boxcar block design. (B) The checkerboard paradigm consisted of 15-second active blocks of contrast-reversing 
(8 Hz) checkerboards interleaved with 15-second presentation of a blank (black) screen as control blocks (rest period). 3 blocks of each contrast 
were interspersed randomly and interleaved with 9 rest blocks. Subjects were asked to press a button when they detected a checkerboard pat-
tern. L, low contrast; M, medium contrast; H, high contrast.
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tion has been reported after long-term deprivation from stroke, 
retinitis pigmentosa, macular degeneration (Stargardt disease or 
cone dystrophy), or traumatic injury to the eye (19, 20, 27–30). 
Although results are suggestive of some degree of brain plastic-
ity around the occipital lobe within the higher-order visual cor-
tex, our results for the most part showed preserved visual cortex 
in LCA2 patients. It may be that retinotopic representation is less 
altered in LCA2 patients until late in life, since these individuals 
have (limited) vision early in life.
fMRI results for CH13’s treated eye showed significant activation 
for only the high-contrast stimuli. In contrast, CH08 and CH09 
demonstrated activation in response to both high- and medium-
contrast stimuli presented to the treated eye. The larger response 
to high and medium-contrast stimuli in younger patients may 
be due to the fact that degenerative retinal changes had not pro-
gressed as far as they had in CH13. Moreover, the younger patients 
were injected in or around the macula, which may have enhanced 
their contrast sensitivity. Indeed, the macula is known to have a 
higher concentration of cone versus rod photoreceptors, a denser 
array of photoreceptors than the peripheral retina, and postrecep-
toral organization that favors higher spatial acuity (8, 31).
Our fMRI results showed no foveal activation in any of the 
patients with high- or medium-contrast stimuli. This may be due 
to lower spatial resolution used for the stimuli (25, 32) or to the 
scotopic light intensity of the fMRI stimuli. These explanations are 
supported by results from a normally sighted age- and sex-matched 
control, in which there was a similar lack of foveal activation. Inter-
estingly, NC01’s fMRI results showed activation similar in pattern 
and magnitude for the high- and medium-contrast stimuli, whereas 
the LCA2 subjects showed greater responses for the high-contrast 
stimuli. This suggests that the treated eye in LCA2 patients, even in 
young subjects, is still not as sensitive to lower-contrast stimuli as 
in normal individuals — at least within the time period evaluated. 
The presence of nystagmus in each patient may have influenced the 
fMRI results by dictating the amount of time the eye can fixate on a 
particular object. Alternatively, amblyopia, which is known to affect 
the degree of cortical activations (26), may have played a role in the 
level of improvement in the LCA patients. Interestingly, psycho-
physical testing of contrast sensitivity before and after treatment 
had not revealed changes in any of the subjects (16, 17). fMRI may 
therefore be more sensitive to changes in contrast sensitivity than 
psychophysical testing in these patients with poor VA.
In summary, our results show that in humans with LCA caused by 
RPE65 mutations, the visual cortex can be made responsive to visu-
al input, even after prolonged (up to 35 years) visual deprivation. 
To our knowledge, this is the first demonstration of stable retino-
topic improvement (lasting at least 2 years) in humans after retinal 
gene therapy, reflected by response of the visual cortex. Our study 
showed not only that the gene therapy–treated retinal cells were 
more sensitive to dim light than were untreated cells, as reflected 
by visual cortex activation, but that treated patients also detected 
lower-contrast objects better with their treated eyes. Future studies 
will involve fMRI before and after gene therapy in both eyes; we 
expect such a comparison to provide further evidence supporting 
the effectiveness of gene therapy for LCA2. Finally, the fMRI find-
ing that the visual cortex can be resuscitated after chronic visual 
deprivation in a rare disease has broader implications. Restoration 
of cortical function in LCA2 through gene augmentation therapy 
provides promise for the outcome of gene therapy for other, more 
common, retinal degenerative diseases with early or late onset.
Methods
Subjects, vector, and surgical delivery. All subjects included in this study had 
LCA2 and were enrolled in a phase I–II open-label dose-escalation study of 
the safety and efficacy of a single subretinal delivery of AAV2-hRPE65v2 
(www.clinicaltrials.gov identifier NCT00516477; refs. 16, 17). The par-
ticipants were 2 affected children, CH09 and CH08 (8 and 9 years of age, 
respectively, at the time of surgery), 1 adult, CH13 (35 years of age at the 
time of surgery), and 1 unaffected normal control child, NC01 (10 years 
of age). The specific RPE65 mutations in CH09, CH08, and CH13 were 
R124X/Lys297del1aggA, F530fs/F530fs, and IVS1 + 5g>a/IVS1 + 5g>a, 
respectively. CH09 and CH08 had received 4.8 × 1010 vector genomes of 
AAV2-hRPE65v2 in a volume of 150 μl, and CH13 received 1.5 × 1011 vector 
genomes in a volume of 300 μl (16, 17). The injections were performed in 
the more impaired eye of each individual: the left eye of CH09 and the right 
eyes of CH08 and CH13 (16, 17).
The locations of retinal detachments created by the subretinal injections 
were recorded with an intraoperative video. Landmarks were identified, 
and the borders of the detachment were later transferred to a composite 
of retinal fundus images acquired at baseline. These borders are likely an 
approximation, however, because immediately after injection, each subject 
was positioned for optimal exposure to AAV as well as the reattachment of 
the retina. The retinas had all reattached by the first postoperative exam 
(15 hours later; refs. 16, 17). Each subject underwent comprehensive base-
line and serial postinjection retinal/visual function testing (16, 17) at pre-
scribed time points (see Results) prior to enrollment in the fMRI study. 
Goldmann VF exams (using the V4e target, the only target the subjects 
could see at baseline) were carried out at baseline and 1 day before fMRI 
testing. fMRI studies were carried out at long-term postinjection time 
points (CH13, 1.0 years; CH09, 1.5 years; CH08, 2 years) after subjects pro-
vided assent with parental permission (CH09 and CH08) or informed con-
sent (CH13). Normally sighted controls were recruited to undergo vision 
testing and fMRI after parental permission and child assent. Results from 
control subject NC01 (matched in age and sex to CH08 and CH09) are 
shown. This study was performed according to procedures approved by the 
Institutional Review Board of CHOP.
Image acquisition. All fMRI data and 3D high-resolution structural brain 
images were acquired on a Siemens 3T Verio system at CHOP using a 
32-channel head coil. Functional data were acquired using the blood 
oxygenation level–dependent technique, acquiring 46 slices with 3 mm 
isotropic resolution (matrix, 64 × 64; TR/TE, 3,000/30 ms) with a total 
acquisition time of 4 minutes, 33 seconds. 5 brain volumes were acquired 
during both active and control blocks for a total of 90 functional vol-
umes. 3 additional volumes were acquired at the beginning of the fMRI 
experiment to reach T1 equilibrium; these were not used in image analysis. 
A transistor-transistor logic (TTL) pulse was used to automatically start 
the stimuli in sync with the start of fMRI acquisition.
In addition to fMRI, isotropic 3D structural high-resolution (1 × 1 × 1 
mm) T1-weighted images of the whole brain were obtained for accu-
rate anatomical representation of visual activation and generation of 
inflated hemispheres. Resonance Technology VisuaStim goggles, featur-
ing a digital display of 500,000 pixels per 0.25 square inch and a 30° 
horizontal field of view, was used to present the fMRI stimuli unilat-
erally to each eye. An MRI-compatible response device (a button that 
the subject pushed when recognizing the stimulus) was used to record 
subject responses. All visual paradigms were programmed in E-Prime 
(Psychology Software Tools Inc.), and all button presses were captured 
via a log file created by E-Prime. Subjects’ button-press responses were 
compared with their fMRI responses to determine whether there was a 
correlation between the subject’s report of seeing the object and activa-
tion of response in the visual cortex.
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fMRI visual paradigms. Checkerboard patterns with a constant light inten-
sity of 5 lux were used in a block design fMRI paradigm, with 3 levels of 
contrast: high, 100%; medium, 34%; low, 10% (Figure 5A). This paradigm 
consisted of 15-second active blocks of contrast-reversing (8-Hz) checker-
boards interleaved with 15 seconds of blank (black) screens as control 
blocks. Subjects were asked to fixate on the plus sign in the center of the 
pattern, or, if they could not see this, were asked to look straight ahead. 
Additionally, subjects were asked to press a button as soon as they could 
detect checkerboard patterns. Stimuli were presented to 1 eye only; thus, 
each subject completed the task twice, once for each eye. Figure 5B shows a 
schematic diagram of the boxcar design that consisted of 3 blocks for each 
contrast, for a total of 9 active blocks interspersed randomly and inter-
leaved with 9 rest blocks.
fMRI processing. All functional data were processed using BrainVoyager-
QX (Brain Innovations; ref. 24). Preprocessing of data included slice scan 
time correction, 3D motion correction, spatial smoothing, and temporal 
filtering. Sinc interpolation was used for scan time correction to ensure 
that all voxels in the volume represented the signal simultaneously. 
A high-pass temporal filter of 2 cycles per run was applied to remove sig-
nal drift. Spatial smoothing was performed using a 3-mm full-width at 
half-maximum (FWHM) Gaussian filter. To rule out excessive motion, all 
functional data sets were additionally processed using the motion correc-
tion algorithm implemented in BrainVoyagerQX, which calculates head 
translation (in millimeters) and rotation (in degree) for each volume in 
relation to the first volume. None of the subjects showed excessive motion 
(±1 mm or greater) during the scan.
Subsequent to preprocessing, functional data were coregistered to the 
individual’s high-resolution 3D-structural T1-weighted images using the 
registration routines in BrainVoyagerQX (24). fMRI results were presented 
as the medial and lateral surfaces of the inflated cortex and flatmap repre-
sentations of each hemisphere. Superimpositions of fMRI activations on 
the inflated and flattened cortex provided additional information with 
improved visualization for cortical activity. Inflated cortices were cre-
ated using an automatic segmentation algorithm implemented in Brain-
VoyagerQX 2.2. Prior to inflation and flattening, the high-resolution 3D 
images were corrected for intensity inhomogeneity using the Vaughan et al. 
correction algorithm (33). Next, the gray matter/white matter border was 
segmented using a region-growing method and analysis of intensity histo-
grams. Morphological operations were used to smooth the borders of the 
segmented data and to separate the left from the right hemisphere. If neces-
sary, manual corrections were made to obtain correct segmentation results. 
Each segmented hemisphere was finally submitted to a “bridge removal” 
algorithm, which ensures the creation of topologically correct mesh rep-
resentations (34). The borders of the 2 resulting segmented subvolumes 
were tessellated to produce a surface reconstruction of each hemisphere. 
Finally, using a fully automatic 3D morphing algorithm (35), the resulting 
meshes were transformed into inflated and flattened cortex representa-
tions. Morphed surfaces were linked to the folded reference meshes so that 
functional data are shown accurately and precisely at the correct location 
on the inflated and flattened representations. This link was also used to 
keep geometric distortions to a minimum during inflation and flattening 
through inclusion of a morphing force that keeps the distances between 
vertices and the area of each triangle of the morphed surface as close as 
possible to the respective values of the reference mesh.
Statistics. All functional data were analyzed in BrainVoyagerQX using the 
GLM, which is mathematically identical to a multiple regression analysis 
and calculates a univariate t statistic for each voxel in the dataset. Each con-
dition (high, medium, and low contrast) was analyzed by specifying a design 
matrix defined as active versus rest conditions followed by application of 
the hemodynamic response function. However, using the GLM approach 
in this manner leads to a multiple-comparison problem stemming from 
the thousands of t tests run (1 per voxel). To account for this problem, we 
used the fdr approach (36) as implemented in BrainVoyagerQX. Given a 
desired fdr, the fdr algorithm calculates a single-voxel threshold, which 
ensures that the voxels beyond that threshold contain no more than the 
specified proportion of false positives. A conservative fdr threshold of 5% 
(q = 0.05) was chosen for all analyses. The corresponding P values were 
reported for each subject/condition, automatically calculated by Brain-
VoyagerQX and based on the division of the probabilities of single tests 
by the number of independent tests. Additionally, cluster thresholds (i.e., 
ccas) were defined to further control for multiple comparisons. We chose 
relaxed thresholds of 20–100 mm2, which allowed for the detection of rela-
tively small but still significant areas of activity in the case of untreated 
eyes, while activity in the treated eye greatly exceeded this threshold (e.g., 
>1,000 cca). Correlations between the activations in the visual cortex and 
the VF maps (predicted and measured) were performed qualitatively and 
based on published retinotopic mapping (37–39).
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